Lv2
108 积分 2022-03-09 加入
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
5天前
已完结
Characterization of the mobilization determinants of pAN12, a small replicon from Rhodococcus erythropolis AN12
2个月前
已完结
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
3个月前
已完结
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
3个月前
已完结
Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo
3个月前
已完结
皖公网安备34019202002308
